🧪 Can genetics predict TNFi response in PsA?

      OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus li

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      🧪 Can genetics predict TNFi response in PsA? OUTPASS GWAS (n=329): High BMI, comorbidities & novel XKR4 locus linked to non-response at 6 months #POS0087 #EULAR2026 @rheumnow
      🎗️ Do targeted therapies raise cancer risk in SpA?
      French nationwide cohort (n=56,591): NO

      In fact, prolonged exp

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      🎗️ Do targeted therapies raise cancer risk in SpA? French nationwide cohort (n=56,591): NO In fact, prolonged exposure REDUCES risk (wHR 0.86), especially haematological. #OP0238 #EULAR2026 @RheumNow https://t.co/dDveAmWpdX
      💊 After TNFi failure in axSpA, switch to IL-17Ai or cycle TNFi?

      ROC-SpA (Phase 4 RCT, n=300):

      NO difference: ASAS

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      💊 After TNFi failure in axSpA, switch to IL-17Ai or cycle TNFi? ROC-SpA (Phase 4 RCT, n=300): NO difference: ASAS40 15.2% vs 14.5% at week 24 #OP0235 #EULAR2026 @RheumNow https://t.co/45gisWiuoM
      ❤️ Do biologics differ in MACE risk in PsA?

      YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retros

      Nelly ZIADE 🍀 Nellziade

      2 months ago
      ❤️ Do biologics differ in MACE risk in PsA? YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts. OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY
      DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema p

      Antoni Chan MD (Prof) synovialjoints

      2 months ago
      DESIR Cohort 10-year data (OP0102): SIJ structural lesions in #axSpA progress slowly, but prior MRI bone marrow oedema predicts later structural damage. bDMARD exposure was associated with less erosion progression supporting early biologic treatment Abstr OP0102 @RheumNow
      After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival

      Jiha Lee JihaRheum

      2 months ago
      After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776
      #OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower over

      Mrinalini Dey DrMiniDey

      2 months ago
      #OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
      After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibi

      Mrinalini Dey DrMiniDey

      2 months ago
      After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow
      What to use in #RA #IL6i v #abatacept post #TNFi-IR?
      H2H #TCZ v #Abatacept

      Same on primary outcome
      #CDAI change wk26
      BU

      Janet Pope Janetbirdope

      2 months ago
      What to use in #RA #IL6i v #abatacept post #TNFi-IR? H2H #TCZ v #Abatacept Same on primary outcome #CDAI change wk26 BUT If #monoRx TCZ better Better retention #TCZ So you decide which is better! Equal v some advantages w #tocilizumab #EULAR2026 @RheumNow @eular_org #OP0205 https://t.co/xdOx4kQCTC
      RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA
      -Primary endpoint DAS28-CRP change wk12
      -2.06 to -2.12 (all doses)

      Aurelie Najm AurelieRheumo

      2 months ago
      RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D
      A new MoA that does not meet it's primary endpoint in RA

      SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib

      ACR2

      Aurelie Najm AurelieRheumo

      2 months ago
      A new MoA that does not meet it's primary endpoint in RA SPECIFI-RA Ph2b oral TNFR1 signal inhibitor balinatunfib ACR20 wk12 NOT significantly diff vs PBO ~48.5–61.8% across doses vs 52.3% PBO Secondary BALI 200 mg QD: ACR50: 36.9% vs 18.5% (nominal p=0.0179) Mechanistic https://t.co/hmZ93JisiO
      EULAR flags
      Understanding Comorbidities in RMD
      • 2026 EULAR Press Release
      2 months ago
      People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
      Roc-SpA study
      Active axSpA dse + inad response to TNFi ➡️switch or cycled
      No significant diff in ASDAS40 at wk24 bet

      sheila RHEUMarampa

      2 months ago
      Roc-SpA study Active axSpA dse + inad response to TNFi ➡️switch or cycled No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi Shared decision is key AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
      What if we let RA patients choose ttmt?

      BACH RCT choice between Filgo / scTNFi vs. standard randomisation
      55% JAKi vs 4

      Aurelie Najm AurelieRheumo

      2 months ago
      What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH
      Is there a ‘window
      Of opportunity’ for Rx
      #GCA w #IL6i
      🤞
      Obtain a better response

      Rx GCA #GC
      #TCZ
      #Upadacitinib

      Janet Pope Janetbirdope

      2 months ago
      Is there a ‘window Of opportunity’ for Rx #GCA w #IL6i 🤞 Obtain a better response Rx GCA #GC #TCZ #Upadacitinib #MTX Study tries to answer if effects of #tocilizumab early vs >8wks is diff N=471, 19% new GCA Early vs late TCZ no dif ❎No Not RCT POS0624 #EULAR2026 @RheumNow

      Catch up on Conference Podcasts

      ×